Study shows that people whose mother had a history of Alzheimer’s disease had a greater risk for the disease compared with ...

In the past two years, the U.S. Food and Drug Administration has approved two monoclonal antibody treatments to slow ...

Cambridge Vision Technology utilises AI-based technology to detect Alzheimer’s disease early on by using ocular biomarkers ...

Researchers discover how amyloid-β and tau pathologies interact to drive early neurophysiological changes and cognitive ...

A new study helps explain why having ApoE4—the gene variant most closely linked to Alzheimer's disease—increases the risk of ...

The ALPS index effectively distinguishes individuals with SCD from those with normal cognition and is correlated with amyloid beta burden.

The plaque building is one component of Alzheimer's disease pathology, the release said. A hallmark of Alzheimer's is the ...

A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...

Despite enormous effort, disease-modifying therapies for Alzheimer's disease, the most common cause of dementia, have proven ...

aDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK bDepartment of Clinical and Movement Neurosciences, Queen Square Brain Bank for Neurological ...

The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...